Diabetes, Vol 37, Issue 8 1044-1048, Copyright © 1988 by American Diabetes Association

ARTICLES

Renal hemodynamics and urinary excretion of 6-keto-prostaglandin F1 alpha and thromboxane B2 in newly diagnosed type I diabetic patients

S Gambardella, D Andreani, A Cancelli, U Di Mario, I Cardamone, G Stirati, GA Cinotti and F Pugliese
Department of Medicine, University of Rome, La Sapienza, Italy.

We have studied the functional importance of renal eicosanoids in renal hemodynamics of seven newly diagnosed insulin-dependent diabetes mellitus (IDDM) patients by treatment with two structurally unrelated inhibitors of cyclooxygenase (i.e., piroxicam and sulindac). Glomerular filtration rate (GFR), renal plasma flow (RPF), daily urinary excretion of 6-keto-prostaglandin F1 alpha (6-keto-PGF1 alpha, the stable hydrolysis product of prostacyclin), and thromboxane B2 (TXB2, the stable hydrolysis product of thromboxane A2) were measured before, during, and after piroxicam (all patients) or sulindac (3 patients) treatment. Urinary excretion of 6-keto-PGF1 alpha was significantly increased (P less than .01) in diabetic patients compared with seven healthy subjects, whereas urinary excretion of TXB2 was unchanged. The baseline value of GFR was significantly (P less than .01) higher in diabetic compared with normal volunteers, whereas baseline RPF was comparable in both groups. Piroxicam (20 mg/day) reduced urinary excretion of 6-keto-PGF1 alpha and TXB2 by 65.7 +/- 26 and 64.6 +/- 33%, respectively. These biochemical changes were temporally associated with the approximately 19% decrease in GFR (P less than .01). A week after discontinuation of the drug, GFR and urinary excretion of 6-keto-PGF1 alpha were still significantly (P less than .05) reduced, whereas urinary excretion of TXB2 returned to control values. In contrast, urinary excretion of eicosanoids and renal function were not affected by sulindac (0.4 g/day) treatment. No functional changes were detected in healthy subjects despite a similar suppression of renal cyclooxygenase activity when they were treated with piroxicam.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. Z.I. Cherney, J. A. Miller, J. W. Scholey, T. J. Bradley, C. Slorach, J. R. Curtis, M. G. Dekker, R. Nasrallah, R. L. Hebert, and E. B. Sochett The Effect of Cyclooxygenase-2 Inhibition on Renal Hemodynamic Function in Humans With Type 1 Diabetes Diabetes, March 1, 2008; 57(3): 688 - 695. [Abstract] [Full Text] [PDF]

				P. Fiorina, G. Perseghin, F. De Cobelli, C. Gremizzi, A. Petrelli, L. Monti, P. Maffi, L. Luzi, A. Secchi, and A. Del Maschio Altered Kidney Graft High-Energy Phosphate Metabolism in Kidney-Transplanted End-Stage Renal Disease Type 1 Diabetic Patients: A cross-sectional analysis of the effect of kidney alone and kidney-pancreas transplantation Diabetes Care, March 1, 2007; 30(3): 597 - 603. [Abstract] [Full Text] [PDF]

				R. Nasrallah and R. L. Hebert Reduced IP receptors in STZ-induced diabetic rat kidneys and high-glucose-treated mesangial cells Am J Physiol Renal Physiol, October 1, 2004; 287(4): F673 - F681. [Abstract] [Full Text] [PDF]

				R. Nasrallah, A. Landry, S. Singh, M. Sklepowicz, and R. L. Hebert Increased expression of cyclooxygenase-1 and -2 in the diabetic rat renal medulla Am J Physiol Renal Physiol, December 1, 2003; 285(6): F1068 - F1077. [Abstract] [Full Text]

				A. C. Pflueger, J. M. Gross, and F. G. Knox Adenosine-induced renal vasoconstriction in diabetes mellitus rats: role of prostaglandins Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1999; 277(5): R1410 - R1417. [Abstract] [Full Text] [PDF]